# US 2025/0144210 A1 · Simplified method of preparing cells for patient administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144210 A1
- Document ID: US20250144210A1
- Status: Published application
- Kind: A1
- Application number: 18/835,253
- Filed: 2023-02-01
- Published: 2025-05-08
- Earliest claimed: 2022-02-01
- Assignees: Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute
- Applicants: Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute
- Inventors: Adam Beebe
- Web page: https://patentgrep.com/patent/US20250144210A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61P 35/00: Antineoplastic agents
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/32: against translation products of oncogenes
- C12N 5/522: {Preservation media}
- C12N 5/562: {Temperature processes, e.g. following predefined temperature changes over time}
- A61M 2039/0027: {for mixing several substances from different containers}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The current disclosure describes simplified methods of preparing cells for patient infusion where the simplified methods result utilize less steps than conventional methods, decreasing required manipulation steps and reducing the time between beginning of cell manipulation for administration and ultimate administration to a patient. Methods of cryopreserving, thawing, and diluting cells and kits for practicing the methods are also provided herein.

## Claims

### Claim 1

A method of preparing a therapeutic cell product for administration to a subject comprising
transferring a volume of therapeutic cells into a first sterile receptacle to create a cell-filled sterile receptacle;
transferring a specified volume of diluent into a second sterile receptacle to create a diluent-filled sterile receptacle;
connecting the cell-filled sterile receptacle to the diluent-filled sterile receptacle with a fluid dispensing connector; and
mixing the volume of cells with the volume of diluent thereby preparing the therapeutic cell product for administration to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first sterile receptacle is a syringe.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second sterile receptacle is a syringe.

### Claim 4 (depends on 2, 3)

The method of claim 2 or 3, wherein the syringe is fitted with a needle.

### Claim 5 (depends on 4)

The method of claim 4, wherein the needle comprises a safety-shielded needle.

### Claim 6 (depends on 4)

The method of claim 4, wherein the needle comprises a 14 gauge needle, 15 gauge needle, 16 gauge needle, 17 gauge needle, 18 gauge needle, 19 gauge needle, 20 gauge needle, 21 gauge needle, 22 gauge needle, 23 gauge needle, 24 gauge needle, 25 gauge needle, 26 gauge needle, or a 27 gauge needle.

### Claim 7 (depends on 4)

The method of claim 4, wherein the needle comprises an 18 gauge safety-shielded needle.

### Claim 8 (depends on 4)

The method of claim 4, wherein the needle is removed before connecting the cell-filled sterile receptacle to the diluent-filled sterile receptacle with a fluid dispensing connector.

### Claim 9 (depends on 1)

The method of claim 1, wherein transferring the volume of cells into the first sterile receptacle comprises drawing cells into the first sterile receptacle.

### Claim 10 (depends on 1)

The method of claim 1, wherein the volume of cells comprises a cell density ranging from 10×106 cells/ml to 325×106 cells/ml.

### Claim 11 (depends on 1)

The method of claim 1, wherein transferring the specified volume of diluent into the second sterile receptacle comprises drawing diluent into the second sterile receptacle.

### Claim 12 (depends on 1)

The method of claim 1, wherein a ratio of volume of cells to specified volume of diluent is selected from 1:5 (v/v), 1:6 (v/v), 1:7 (v/v), 1:8 (v/v), 1:9 (v/v), 1:10 (v/v), 1:11 (v/v), 1:12 (v/v), 1:13 (v/v), 1:14 (v/v), 1:15 (v/v), or 1:16 (v/v).

### Claim 13 (depends on 1)

The method of claim 1, wherein a ratio of volume of cells to specified volume of diluent is 1:10 (v/v).

### Claim 14 (depends on 13)

The method of claim 13, wherein the specified volume of diluent is at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, or at least 15 times the volume of cells.

### Claim 15 (depends on 13)

The method of claim 13, wherein the specified volume of diluent is 9 times the volume of cells.

### Claim 16 (depends on 1)

The method of claim 1, wherein the diluent comprises an isotonic solution.

### Claim 17 (depends on 16)

The method of claim 16, wherein the isotonic solution comprises less than 10 mg/ml sodium chloride, less than 10 mg/mL sodium acetate, less than 10 mg/mL sodium gluconate, less than 10 mg/mL potassium chloride, and less than 10 mg/mL magnesium chloride hexahydrate.

### Claim 18 (depends on 16)

The method of claim 16, wherein the isotonic solution comprises 2.5-7.5 mg/mL sodium chloride, 1.5-4.0 mg/mL sodium acetate, 2.5-7.5 mg/mL sodium gluconate, 0.1-0.8 mg/mL potassium chloride, and 0.1-0.5 mg/mL magnesium chloride hexahydrate.

### Claim 19 (depends on 16)

The method of claim 16, wherein the isotonic solution comprises 5.26 mg/mL sodium chloride, 2.22 mg/mL sodium acetate, 5.02 mg/mL sodium gluconate, 0.37 mg/mL potassium chloride, and 0.30 mg/mL magnesium chloride hexahydrate.

### Claim 20 (depends on 16)

The method of claim 16, wherein the isotonic solution further comprises HCl for pH adjustment.

### Claim 21 (depends on 16)

The method of claim 16, wherein the isotonic solution further comprises NaOH for pH adjustment.

### Claim 22 (depends on 1)

The method of claim 1, wherein the fluid dispensing connector comprises at least 2 ports.

### Claim 23 (depends on 22)

The method of claim 22, wherein the fluid dispensing connector comprises a first port and a second port.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cell-filled sterile receptacle is attached to the first port on the fluid dispensing connector and the diluent-filled sterile receptacle is attached to the second port on the fluid dispensing connector.

### Claim 25 (depends on 1)

The method of claim 1, wherein mixing the volume of cells with the volume of diluent comprises forcing cells and diluent to flow between the cell-filled sterile receptacle, fluid dispensing connector, and diluent-filled sterile receptacle to create a total mixed volume of cells and diluent.

### Claim 26 (depends on 1)

The method of claim 1, wherein the first sterile receptacle comprises a first syringe, the second sterile receptacle comprises a second syringe, and the mixing comprises pushing a plunger on the first syringe and the second syringe consecutively and repetitively such that the volume of cells and volume of diluent mix to create a total mixed volume of cells and diluent.

### Claim 27 (depends on 25, 26)

The method of claim 25 or 26, wherein the total mixed volume is less than 10 mL, less than 9 mL, less than 8 mL, less than 7 ml, less than 6 mL, less than 5 mL, less than 4 mL, less than 3 mL, less than 2 mL, or less than 1 mL.

### Claim 28 (depends on 27)

The method of claim 27, wherein the total mixed volume is less than 5 mL.

### Claim 29 (depends on 25)

The method of claim 25, comprising transferring the total mixed volume into either the cell-filled sterile receptacle or the diluent-filled sterile receptacle to create a product-filled sterile receptacle.

### Claim 30 (depends on 29)

The method of claim 29, comprising transferring the total mixed volume into the cell-filled sterile receptacle to create the product-filled sterile receptacle.

### Claim 31 (depends on 29)

The method of claim 29, comprising transferring the total mixed volume into the diluent-filled sterile receptacle to create the product-filled sterile receptacle.

### Claim 32 (depends on 29)

The method of claim 29, comprising removing the product-filled sterile receptacle from the fluid dispensing connector.

### Claim 33 (depends on 29)

The method of claim 29, comprising plugging the product-filled sterile receptacle with luer plug.

### Claim 34 (depends on 29)

The method of claim 29, comprising storing the product-filled sterile receptacle in a vessel on dry ice.

### Claim 35 (depends on 29)

The method of claim 29, comprising transferring the product-filled sterile receptacle to a clinic for administration to the subject.

### Claim 36 (depends on 1)

The method of claim 1, wherein the subject has cancer.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cancer is a central nervous system tumor, glioma, ependymoma, medulloblastoma, germ cell tumor, atypical teratoid, primitive neuroectodermal tumor, choroid plexus carcinoma, or pineoblastoma.

### Claim 38 (depends on 36)

The method of claim 36, wherein the cancer is a central nervous system tumor.

### Claim 39 (depends on 1)

The method of claim 1, wherein the therapeutic cells comprise cells from the subject.

### Claim 40 (depends on 39)

The method of claim 39, wherein the cells from the subject comprise immune cells.

### Claim 41 (depends on 40)

The method of claim 40, wherein the immune cells comprise T cells.

### Claim 42 (depends on 41)

The method of claim 41, wherein the T cells are CD4+ T cells.

### Claim 43 (depends on 41)

The method of claim 41, wherein the T cells are CD8+ T cells.

### Claim 44 (depends on 41)

The method of claim 41, wherein the T cells are CD4+ and CD8+ T cells.

### Claim 45 (depends on 41)

The method of claim 41, wherein the T cells are genetically modified to express a therapeutic molecule.

### Claim 46 (depends on 45)

The method of claim 45, wherein the therapeutic molecule comprises a chimeric antigen receptor (CAR).

### Claim 47 (depends on 41)

The method of claim 41, wherein the T cells are genetically modified to express a CAR and EGFRt.

### Claim 48 (depends on 46, 47)

The method of claim 46 or 47, wherein the CAR is an anti-Her2 CAR.

### Claim 49 (depends on 1)

The method of claim 1, further comprising administering the therapeutic cell product to the subject.

### Claim 50 (depends on 49)

The method of claim 49, wherein the administering comprises injection, infusion, implantation, or transplantation.

### Claim 51 (depends on 49)

The method of claim 49, wherein the administering comprises injecting the therapeutic cell product at the site of a tumor resection in the subject.

### Claim 52 (depends on 49)

The method of claim 49, wherein the administering comprises injecting the therapeutic cell product into the ventricular system of the central nervous system of the subject.

### Claim 53 (depends on 49)

The method of claim 49, wherein the administering comprises infusion.

### Claim 54 (depends on 1)

The method of claim 1, wherein the subject is greater than 1 year old, greater than 2 years old, greater than 3 years old, greater than 4 years old, greater than 5 years old, greater than 6 years old, greater than 7 years old, greater than 8 years old, greater than 9 years old, greater than 10 years old, greater than 11 years old, greater than 12 years old, greater than 13 years old, greater than 14 years old, greater than 15 years old, greater than 16 years old, greater than 17 years old, greater than 18 years old, greater than 19 years old, greater than 20 years old, greater than 21 years old, greater than 22 years old, greater than 23 years old, greater than 24 years old, or greater than 25 years old.

### Claim 55 (depends on 1)

The method of claim 1, wherein the subject is greater than 1 year old.

### Claim 56 (depends on 1)

The method of claim 1, wherein the subject is less than 26 years old.

### Claim 57 (depends on 1)

The method of claim 1, wherein the subject is greater than 26 years old.

### Claim 58 (depends on 1)

The method of claim 1, wherein the method does not comprise centrifugation.

### Claim 59 (depends on 1)

The method of claim 1, wherein the method does not comprise sterile welding.

### Claim 60 (depends on 1)

The method of claim 1, wherein the method does not comprise a wash step.

### Claim 61 (depends on 1)

The method of claim 1, wherein the method further comprises cryopreserving the therapeutic cells to create cryopreserved cells and thawing the cryopreserved cells to create thawed therapeutic cells before transferring the volume of thawed therapeutic cells into the first sterile receptacle.

### Claim 62 (depends on 61)

The method of claim 61, wherein the cryopreserving comprises suspending the therapeutic cells in a freezing medium and reducing the temperature to a cryopreservation temperature to create cryopreserved cells.

### Claim 63 (depends on 62)

The method of claim 62, wherein the freezing medium comprises a cryopreservative.

### Claim 64 (depends on 63)

The method of claim 63, wherein the cryopreservative is DMSO.

### Claim 65 (depends on 62)

The method of claim 62, wherein the freezing medium comprises 5% DMSO.

### Claim 66 (depends on 62)

The method of claim 62, wherein the cryopreservation temperature ranges from −205° C. to −60° C.

### Claim 67 (depends on 62)

The method of claim 62, wherein the cryopreserved cells are stored in liquid nitrogen.

### Claim 68 (depends on 61)

The method of claim 61, wherein the thawing comprises incubating the cryopreserved cells at progressively increasing temperatures.

### Claim 69 (depends on 68)

The method of claim 68, wherein the incubating comprises putting the cryopreserved cells in a temperature controlled incubator.

### Claim 70 (depends on 69)

The method of claim 69, wherein the temperature controlled incubator comprises a controlled water bath, a temperature controlled oven, or an automated thawing device.

### Claim 71 (depends on 61)

The method of claim 61, wherein the thawing comprises using an automated thawing device.

### Claim 72 (depends on 61)

The method of claim 61, wherein the thawing comprises incubating the cryopreserved cells at a temperature ranging from 15° C. to 30° C.

### Claim 73 (depends on 61)

The method of claim 61, wherein the thawing comprises incubating the cryopreserved cells at a temperature ranging from 30° C. to 45° C.

### Claim 74 (depends on 61)

The method of claim 61, wherein the thawing comprises incubating the cryopreserved cells at a temperature of 37° C.

### Claim 75 (depends on 61)

The method of claim 61, further comprising determining a viability of the thawed therapeutic cells.

### Claim 76 (depends on 75)

The method of claim 75, wherein the viability of thawed therapeutic cells is greater than 65%.

### Claim 77 (depends on 75)

The method of claim 75, wherein the viability of thawed therapeutic cells is greater than 70%.

### Claim 78

A method for formulation of therapeutic cells for administration to a subject comprising thawing cryopreserved cells to create thawed cells; transferring a volume of thawed cells into a first syringe to create a cell-filled syringe; transferring a specified volume of diluent into a second syringe to create a diluent-filled syringe; connecting the cell-filled syringe to the diluent-filled syringe with a fluid dispensing connector; mixing the volume of cells with the volume of diluent to create a total mixed volume; and transferring the total mixed volume into either the cell-filled syringe or the diluent-filled syringe.

### Claim 79 (depends on 78)

The method of claim 78, wherein the thawing comprises using an automated thawing device.

### Claim 80 (depends on 78)

The method of claim 78, comprising a ratio of volume of thawed cells to volume of diluent of 1:5 (v/v), 1:6 (v/v), 1:7 (v/v), 1:8 (v/v), 1:9 (v/v), 1:10 (v/v), 1:11 (v/v), 1:12 (v/v), 1:13 (v/v), 1:14 (v/v), 1:15 (v/v), or 1:16 (v/v).

### Claim 81 (depends on 78)

The method of claim 78, comprising a ratio of volume of thawed cells to volume of diluent of 1:10 (v/v).

### Claim 82 (depends on 78)

The method of claim 78, wherein the total mixed volume is transferred to the cell-filled syringe.

### Claim 83 (depends on 78)

The method of claim 78, comprising disconnecting the fluid dispensing connector from the cell-filled syringe and plugging the cell-filled syringe with a luer plug.

### Claim 84 (depends on 78)

The method of claim 78, wherein the total mixed volume is transferred to the diluent-filled syringe.

### Claim 85 (depends on 78)

The method of claim 78, comprising disconnecting the fluid dispensing connector from the diluent-filled syringe and plugging the diluent-filled syringe with a luer plug.

### Claim 86

A kit for dilution of cell product comprising syringes, needles, fluid dispensing connector, and diluent.

### Claim 87 (depends on 86)

The kit of claim 86, comprising at least two syringes.

### Claim 88 (depends on 86)

The kit of claim 86, wherein the needles attach to the syringes.

### Claim 89 (depends on 86)

The kit of claim 86, wherein the needles comprise 18 gauge safety-shielded needles.

### Claim 90 (depends on 86)

The kit of claim 86, wherein the fluid dispensing connector attaches to the syringes.

### Claim 91 (depends on 86)

The kit of claim 86, wherein the diluent comprises an isotonic solution.

### Claim 92 (depends on 91)

The kit of claim 91, wherein the isotonic solution comprises 5.26 mg/mL sodium chloride, 2.22 mg/mL sodium acetate, 5.02 mg/mL sodium gluconate, 0.37 mg/mL potassium chloride, and 0.30 mg/mL magnesium chloride hexahydrate.

### Claim 93 (depends on 86)

The kit of claim 86, comprising NaOH and/or HCl for pH adjustment.

### Claim 94 (depends on 86)

The kit of claim 86, comprising a luer plug.

### Claim 95 (depends on 86)

The kit of claim 86, comprising disinfectant.

### Claim 96 (depends on 95)

The kit of claim 95, wherein the disinfectant comprises povidone-iodine, isopropyl alcohol, ethanol, methanol, and/or hydrogen peroxide.

### Claim 97 (depends on 95)

The kit of claim 95, wherein the disinfectant comprises povidone-iodine and/or isopropyl alcohol swabs.

### Claim 98 (depends on 86)

The kit of claim 86, comprising instructions for dilution of cell product.
